Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Blockchain Means For Health Care in 2019

The health care industry has long been plagued by inefficiency and complex, independent systems to collect the troves of data thrown its way. Now, a new report from PricewaterhouseCoopers highlights the benefits that adopting a blockchain system can have on a hospital’s network infrastructure and for the patients and doctors in the middle of it….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The health care industry has long been plagued by inefficiency and complex, independent systems to collect the troves of data thrown its way. Now, a new report from PricewaterhouseCoopers highlights the benefits that adopting a blockchain system can have on a hospital’s network infrastructure and for the patients and doctors in the middle of it.

Blockchain, often associated with cryptocurrency, is a new development in the IT world. Regarding the health care industry, its focus lies on decentralizing network paths that enable the flow and transfer of information. Blockchain is best defined as a decentralized ledger of all transactions in a network. This eliminates the need for a third-party intermediary to confirm transactions within a network—one of the biggest problems slowing down the health care industry.

Streamlining data is important for an industry that handles not just a high volume of data, but also highly sensitive and impactful data for patients. From supply chain management to risk and regulatory functions, there is an incredible amount of work that ends up in the hands of a third-party entity.

“With blockchain technology, each company in the supply chain would control one or several nodes. Each time a company entered into a transaction with another company in the supply chain, that transaction would be recorded and validated on the blockchain. This would simplify the transfer of data and allow product recipients to validate their provenance with greater certainty,” the report stated.

It would also significantly simplify transaction reconciliations and data transfers. According to the report, “blockchain makes it easier to transfer, share and check data automatically, processes that now require numerous (and sometimes manual) handoffs as a product moves through the supply chain.”

There are even implications that spread to the doctors and physicians themselves. One of the many time-consuming tasks of being a licensed doctor is credentialing. Each physician in a practice submits an average of 18 applications for credentialing each year.

That requires 80 minutes—including 69 minutes of staff time and 11 of physician time—per physician, according to The National Association of Medical Staff Services. NAMSS conservatively estimates that most physician credentialing takes more than 120 days, while health plan enrollment takes 60 to 180 days.

The Council for Affordable Quality Health care estimates that payers spend more than $2 billion each year maintaining provider databases, and according to the report, 75 percent could be eliminated by establishing a single source of truth, such as a blockchain. This method saves money for the providers and frees up doctors to visit more patients and transfer their data without mistakes.

Blockchain technology is going to change the way major health care providers manage data. The system has the potential to save billions in lost revenue and drastically reduce error when it comes to patient data and pharmaceuticals. In order for this network to function, however, it is imperative for other companies to participate.

According to PwC, “While 49 percent of health care technology executives surveyed by PwC in its 2018 global blockchain survey said their companies were developing blockchain solutions, many also said they understood they would need to work through challenges on the way to implementation…Constructing a governance structure agreeable to all parties can take time and effort.” This time and effort seems destined to be worth it for the future of the health care industry.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512